- Home
- ESPR vs DSGN Comparison
ESPR vs DSGN Comparison
Compare ESPR & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- DSGN
- Stock Information
- Founded
- ESPR 2008
- DSGN 2017
- Country
- ESPR United States
- DSGN United States
- Employees
- ESPR N/A
- DSGN N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- ESPR Health Care
- DSGN Health Care
- Exchange
- ESPR Nasdaq
- DSGN Nasdaq
- Market Cap
- ESPR 220.0M
- DSGN 208.9M
- IPO Year
- ESPR 2013
- DSGN 2021
- Fundamental
- Price
- ESPR $1.40
- DSGN $3.82
- Analyst Decision
- ESPR Buy
- DSGN Hold
- Analyst Count
- ESPR 6
- DSGN 1
- Target Price
- ESPR $6.50
- DSGN $4.00
- AVG Volume (30 Days)
- ESPR 5.1M
- DSGN 94.3K
- Earning Date
- ESPR 08-05-2025
- DSGN 08-12-2025
- Dividend Yield
- ESPR N/A
- DSGN N/A
- EPS Growth
- ESPR N/A
- DSGN N/A
- EPS
- ESPR N/A
- DSGN N/A
- Revenue
- ESPR $259,574,000.00
- DSGN N/A
- Revenue This Year
- ESPR $6.10
- DSGN N/A
- Revenue Next Year
- ESPR N/A
- DSGN N/A
- P/E Ratio
- ESPR N/A
- DSGN N/A
- Revenue Growth
- ESPR 12.99
- DSGN N/A
- 52 Week Low
- ESPR $0.69
- DSGN $2.60
- 52 Week High
- ESPR $3.94
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- ESPR 58.85
- DSGN 45.61
- Support Level
- ESPR $1.13
- DSGN $3.76
- Resistance Level
- ESPR $1.74
- DSGN $4.19
- Average True Range (ATR)
- ESPR 0.17
- DSGN 0.22
- MACD
- ESPR 0.01
- DSGN -0.03
- Stochastic Oscillator
- ESPR 30.61
- DSGN 8.82
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.